CAR T cell toxicity: Current management and future directions Journal Article


Authors: Yáñez, L.; Sánchez-Escamilla, M.; Perales, M. A.
Article Title: CAR T cell toxicity: Current management and future directions
Abstract: By late 2018, 2 chimeric antigen receptor T (CAR T) cell products have been approved by US and European regulatory authorities. Tisagenlecleucel (Kymriah, Novartis) is indicated in the treatment of patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse, or adult patients with large B-cell lymphoma relapsed or refractory (r/r) after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Axicabtagene ciloleucel (Yescarta, Kite) is indicated for the treatment of adult patients with large B-cell lymphoma relapsed or refractory after 2 or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (ZUMA-1 trial). This review will offer a practical guide for the recognition and management of the most important toxicities related to the use of the current commercial CAR T cells, and also highlight strategies to diminish these side effects in the future.
Keywords: neurotoxicity; biomarkers; transplantation; therapy; adoptive immunotherapy; versus-host-disease; malignancies; cd19; cytokine-release syndrome; remissions
Journal Title: HemaSphere
Volume: 3
Issue: 2
ISSN: 2572-9241
Publisher: Lippincott Williams & Wilkins  
Date Published: 2019-04-01
Start Page: e186
Language: English
ACCESSION: WOS:000507916200012
DOI: 10.1097/hs9.0000000000000186
PROVIDER: wos
PMCID: PMC6746032
PUBMED: 31723825
Notes: Review -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Miguel-Angel Perales
    465 Perales